National Cancer Institute–Designated Comprehensive Cancer Center
The National Cancer Institute (NCI), part of the National Institutes of Health, awards Comprehensive Cancer Center designation to centers around the country that have shown their commitment to laboratory research, clinical trials, education and training, community outreach, and the development of more effective approaches to cancer prevention, diagnosis, and treatment.
As one of 51 NCI-designated Comprehensive Cancer Centers, Perlmutter Cancer Center is among the top cancer centers in the United States. This distinction indicates that when you choose Perlmutter Cancer Center, you are cared for by professionals who understand the impact cancer can have on the lives of individuals, families, and communities. Our team knows the value of working together to discover and deliver the most advanced treatments to patients and their families, to educate healthcare professionals and the public, and to reach out to diverse and underserved populations.
We are one of 12 cancer centers in the Northeast to receive the NCI’s Comprehensive Cancer Center designation.
We are known for our innovative technologies and clinical trials, and our team approach to cancer research. Our experienced leadership is helping shape the future of cancer research and state-of-the-art patient care facilities.
Ranked Among Top 25 Cancer Centers in the Country, According to U.S. News & World Report’s “Best Hospitals”
U.S. News & World Report has ranked NYU Langone’s Perlmutter Cancer Center among the top 25 hospitals for cancer in the 2023–2024 U.S. News & World Report “Best Hospitals” rankings. In addition, the publication rated colon cancer surgery, lung cancer surgery, ovarian cancer surgery, and prostate cancer surgery, uterine cancer surgery, and leukemia, lymphoma, and myeloma, as “high performing” procedures and cancer-related conditions for adults.
In recognition of their work, researchers at Perlmutter Cancer Center and the Ronald O. Perelman Department of Dermatology received a Melanoma Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI). This grant supports research to discover biomarkers and other tools for predicting whether immunotherapies can effectively treat melanoma.
Perlmutter Cancer Center researchers were also awarded a new NCI Research Program Project grant (P01) that aims to study the impact of chromosomal changes on the physical characteristics of cancer cells and tumor progression. A second NCI P01 grant, which was recently renewed, focuses on how bladder cancer develops.
Our faculty continue to advance cancer diagnosis and treatment, including new breakthroughs in treating intractable lung cancer and triple negative breast cancer, identifying oral bacteria tied to risk of esophageal cancer, a new laser ablation technique for brain tumors that are difficult to treat, and the development of a 580-gene diagnostic panel for cancer-associated mutations.
American College of Surgeons Commission on Cancer Accreditation
NYU Langone Health has received three-year accreditation with commendation from the American College of Surgeons Commission on Cancer. This honor recognizes our commitment to providing you with access to the latest advances in cancer care, including clinical trials, delivered by a team focused on coordinating the best treatment option for you.
U.S. News & World Report’s “Best Hospitals” ranks NYU Langone one of the top hospitals in the country for cancer care.
It also is a reflection of our commitment to cancer prevention, early detection, education, and support services.
Magnet Recognition for Nursing
NYU Langone Health has received the highest national honor in nursing excellence: Magnet® recognition by the American Nurses Credentialing Center (ANCC). This honor recognizes healthcare organizations that demonstrate excellence in nursing services. Magnet® designation is the gold standard for nursing practice.
Our Magnet® recognition means that you are cared for by a nursing team made up of experts in patient care and patient education. Our nurses’ compassion helps people better manage the symptoms of their disease and accommodates their special needs.
Foundation for the Accreditation of Cellular Therapy (FACT) Certification
Perlmutter Cancer Center’s Blood and Marrow Transplant Program is certified by the Foundation for the Accreditation of Cellular Therapy (FACT) to perform autologous and allogeneic transplants for adult patients, and autologous transplants for pediatric patients. This certification recognizes the high-quality patient care and laboratory practices used to treat people with various blood cancers and blood disorders.